血必净注射液对凝血功能障碍危重病患者的临床价值研究

目的 探讨血必净注射液在有凝血功能障碍危重病患者中的临床应用价值.方法 将67例入住ICU有凝血功能障碍的危重病患者随机分为治疗组34例,对照组33例.两组患者均给予常规综合治疗,治疗组同时给予血必净注射液治疗7 d.治疗前后分别取静脉血,检测凝血功能相关指标凝血酶原时间(PT)、凝血酶时间(TT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)和血小板计数(PLT)]及血浆降钙素原(PCT)、白细胞介素-6(IL-6)、C-反应蛋白(CRP)浓度.结果 治疗组治疗前后PLT、PT、APTT、TT、FIB及CRP、IL-6、PCT、急性生理及慢性健康状况评分Ⅱ(APACHEⅡ)比较差异均有统计学意义(P<0.05);治疗后两组PLT、PT、FIB及IL-6、PCT、APACHEⅡ评分比较差异均有统计学意义(P<0.05).结论 血必净注射液可以明显改善危重病患者的凝血功能障碍,减少炎症因子的生成,具有很高的临床应用价值.

Clinical value of Xuebijing injection in coagulation dysfunction of critical illness patients

To study the clinical value of Xuebijing injection in coagulation dysfunction of critical illness patients. Methods 67 patients admitted to the Intensive Care Unit were divided into treatment groups (Xuebijing injection therapy) with 34 cases, and control groups with 33 cases. Two groups were conventionally received regular treatment. At the same time, the treatment group was treated with Xuebijing injection for a week. The coagulation function indexes and the levels of plasma procalcitonin, C-reactive protein and interleukin-6 were measured pre- and post- treatment. Results After Xuebijing treatment for a week, in treatment group, there was significant difference in PLT, PT, APTT, TT, FIB and CRP, IL-6, PCT, APACHEⅡ between pre- and post- treatment(P﹤0.05).There were significant differences in PLT, PT, FIB and IL-6, PCT, APACHEⅡbetween two groups after the treatment(P﹤0.05). Conclusion Xuebijing injection could improve coagulation indexes in critical illness patients with coagulation dysfunction, reduce the generation of inflammatory factor, and have important clinical value in the treatment of critical illness patients.